P53 gene can affect ovarian cancer prognosis
The prognosis and outcome: Common and prognosis factors: • clinical stage and is closely related to survival; • histological type and grade pathology and prognos...
P53 gene can cure ovarian cancer Abstract: a group P53 mutations in the genes in patients with advanced ovarian cancer by more cycles of P53 gene therapy and chemotherapy, r...
For a long time, ovarian cancer is malignant gynecologic tumors in the highest degree. In the United States, the mortality rate since 1979 as medical research has not progressed any lower, always maintained at about 9.8 per 100,000.
Currently known ovarian cancer in a related gene p53 gene. The human gene that regulates the transcription of certain genes, thereby inhibiting cell proliferation and repair damage cells. The function of this gene defect could lead to abnormal cell proliferation occurring.
Recently, in November published "Cancer" magazine published in the latest research results show that: void in the p53 gene mutation in patients with ovarian cancer than missense mutation of the p53 gene, the prognosis is even worse. (The former average survival was 1.49 years; The latter 3.6) It is noteworthy that although the p53 gene mutation on the invalidity of the prognosis of patients with ovarian cancer have great impact and its Missense mutations and excessive expression of the patient is very small impact.
Scientists in the study found that the p53 gene mutation may lead to the nullification of its top produce a truncated protein, the DNA binding protein and not without repair damage cell activity. In addition, this mutant cells also can directly reduce the sensitivity to chemotherapy drugs to induce cancer cell resistance.
The monoclonal antibody staining DO7 not accurately detect the p53 gene-positive cancer, the previous all alone on immunohistochemistry (IHC) test on the p53 gene to varying degrees, are subject to the technical constraints. In the study, the scientists also used the two detection methods: IHC DO7 antibody staining of p53 overexpression of the gene; In the p53 gene sequencing this before its single strand conformation polymorphism (SSCP). The pilot study was mainly targeted at the 40 to 70 age some of the advanced ovarian cancer patients.
Scientists pointed out that invalid mutation of the p53 gene in patients with poor prognosis of ovarian cancer because of its high-risk early cancer metastasis. Scientists recommended that such patients, if possible as early as possible p53 gene to gene therapy.
Ovarian cancer prognosis and outcome Ovarian cancer The prognosis and outcome Common and prognosis factors: • clinical stage and is closely related to survival; • his...
British scientists find anti-female ovarian cancer gene British "Nature Genetics" recently published text, British scientists have found a gene named OPCML. 90% of women suffering from...
Beware of genetic factors of ovarian cancer The possible risk of ovarian cancer risk factors, including age, not infertility, diet, ovulation drug therapy. But if family history of br...
Experience with ovarian cancer Treatment of ovarian cancer is still surgery and chemotherapy, although postoperative adjuvant systemic chemotherapy has been the effect cer...
Cervical cancer virus with head and neck cancer Usually that cervical cancer is a certain type of human papilloma virus (HPV) caused. Now Johns Hopkins University researchers think that so...
Epithelial ovarian cancer proven mechanism Henan Medical University, a professor of obstetrics and gynecology buildings Qiao Yu, graduate students and others Rui - Xia Guo recent stud...
Advanced ovarian cancer patients quality of life
Tags: age, anti, body, cancer, cause, cell, cells, chemotherapy, drug, drugs, early, eat, ert, gene, life, malignant, metastasis, method, mutation, ovarian, p53, patients, poor, positive, prognosis, protein, rate, reduce, risk, study, survival, therapy, time, tumor, tumors